亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

深圳市思科達生物技術有限公司  

專業經營化學標準品,對照品

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:楊森
  • 電話:0755-89218244
  • 郵件:lq@szskerd.com
  • 傳真:0755-28984072
  • QQ:793285927
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 索拉菲尼
索拉菲尼
單價 面議對比
詢價 暫無
發貨 廣東深圳市付款后3天內
品牌 深圳市思科達生物技術有限公司
過期 長期有效
更新 2014-12-02 13:09
 
詳細信息
 產品名稱:索拉菲尼 雜質 標準品 對照品 284461-73-0

產品關鍵詞:索拉菲尼 雜質 標準品 對照品 284461-73-0

索拉菲尼                                                Sorafenib                                     100mg

索拉菲尼雜質A                                    Sorafenib Impurity A                  10mg/25mg/50mg

索拉菲尼雜質B                                    Sorafenib Impurity B                  10mg/25mg/50mg

索拉菲尼雜質C                                    Sorafenib Impurity C                  10mg/25mg/50mg

索拉菲尼雜質D                                    Sorafenib Impurity D                  10mg/25mg/50mg

索拉菲尼雜質E                                    Sorafenib Impurity E                  10mg/25mg/50mg

索拉菲尼雜質F                                     Sorafenib Impurity F                  10mg/25mg/50mg

索拉菲尼雜質G                                    Sorafenib Impurity G                  10mg/25mg/50mg

索拉菲尼雜質H                                    Sorafenib Impurity H                  10mg/25mg/50mg

索拉菲尼雜質I                                     Sorafenib Impurity I                   10mg/25mg/50mg

索拉菲尼雜質J                                     Sorafenib Impurity J                   10mg/25mg/50mg

索拉菲尼雜質K                                    Sorafenib Impurity K                  10mg/25mg/50mg

©2025 深圳市思科達生物技術有限公司 版權所有   技術支持:化工網   訪問量:13002  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |